Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Lancet HIV. 2016 Sep 19;3(11):e529–e538. doi: 10.1016/S2352-3018(16)30053-4

Table 1.

Demographics and sample characteristics at baseline.

TAU
(n=49)
CBT
(n=94)
ISP
(n=97)
Age M (SD) 47·1 (8·7) 48·6 (8·0) 46·5 (8·6)
Gender n (%)
    Male 36 (73·5) 72 (76·6) 57 (58·8)
    Female 13 (26·5) 22 (23·4) 40 (41·2)
Race n*
    African American/Black 14 26 28
    Caucasian/White 31 63 62
    Other 7 10 14
Hispanic/Latino n (%)
    Yes 7 (14·3) 7 (7·4) 12 (12·4)
    No 42 (85·7) 87 (92·6) 85 (87·6)
Education n (%)
    Partial high school or less 9 (18·4) 11 (11·7) 13 (13·4)
    High school graduate 12 (24·5) 25 (26·6) 28 (28·9)
    Partial college 14 (28·6) 32 (34) 24 (24·7)
    College graduate 14 (28·6) 26 (27·7) 32 (33)
On Disability n (%)
    Yes 32 (65·3) 55 (58·5) 52 (53·6)
    No 17 (34·7) 39 (41·5) 45 (46·4)
Sexual Orientation n (%)
    Exclusively homosexual 26 (53·1) 29 (30·9) 26 (26·8)
    Homosexual with some heterosexual experience 3 (6·1) 22 (23·4) 17 (17·5)
    Bisexual 2 (4·1) 4 (4·3) 8 (8·2)
    Heterosexual with some homosexual experience 3 (6·1) 9 (9·6) 6 (6·2)
    Exclusively heterosexual 15 (30·6) 30 (31·9) 40 (41·2)
MEMs based adherence 71.29 (24.43) 72.33 (22.69) 71.77 (25.53)
Clinical Global Impression (CGI) M (SD) 4.51 (1.16) 4.33 (1.26) 4.67 (1.14)
MADRS M (SD) 24.33 (7.95) 23.48 (8.04) 26.86 (8.30)
CESD M (SD) 29.33 (8.36) 26.31 (6.80) 27.42 (7.71)
CD4 M (SD) 560.33 (256.88) 585.44 (284.28) 578.26 (275.40)
Viral Load (log 10) M (SD) 1.96 (0.26) 2.14 (0.73) 1.98 (0.48)
Detectable viral load, proportion .15 .17 .11
*

Race category not mutually exclusive, as participants could choose more than one category. Ns for viral load (47, 92, 92), CD4 (48, 91, 92), and MEMs (49, 92, 94) for ETAU, CBT-AD and ISP-AD respectively are lower than the other measures due to issues with lab processing or user/technology issues with starting MEMs.